Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Transfer from incubator to cot at lower vs higher body weight Duration from transfer to cot to discharge home (days) · patients with preterm infants Transfer of preterm infants from incubator to open cot at lower versus higher body weight (2011) · Cochrane | no estimate extracted | 2 studies · 276 participants | High |
Transfer from incubator to cot at lower vs higher body weight Postmenstrual age at discharge · patients with preterm infants Transfer of preterm infants from incubator to open cot at lower versus higher body weight (2011) · Cochrane | no estimate extracted | 2 studies · 276 participants | High |
Transfer from incubator to cot at lower vs higher body weight Length of hospital stay (days) · patients with preterm infants Transfer of preterm infants from incubator to open cot at lower versus higher body weight (2011) · Cochrane | no estimate extracted | 2 studies · 276 participants | High |
Transfer from incubator to cot at lower vs higher body weight Proportion of infants exclusive breastfeeding at discharge · patients with preterm infants Transfer of preterm infants from incubator to open cot at lower versus higher body weight (2011) · Cochrane | RR 1 [0.81, 1.24] | 2 studies · 276 participants | High |
Intervention NR Soreness on day 1 Scale from: 0 to 100. · people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | no estimate extracted | 3 studies · 70 participants | Low |
Intervention NR Soreness on day 2 Scale from: 0 to 100. · people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | no estimate extracted | 2 studies · 40 participants | Low |
Intervention NR Soreness on day 1 Scale from: 0 to 100. · people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | no estimate extracted | 4 studies · 127 participants | Low |
Intervention NR Soreness on day 2 Scale from: 0 to 100. · people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | no estimate extracted | 5 studies · 158 participants | Low |
Intervention NR Soreness on day 1 Scale from: 0 to 100. · people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | no estimate extracted | 7 studies · 197 participants | Low |
Intervention NR Soreness on day 2 Scale from: 0 to 100. · people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | no estimate extracted | 7 studies · 198 participants | Low |
Intervention NR Soreness in preceding week Scale from: 0 to 100. · patients with people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | no estimate extracted | 1 study · 2377 participants | Moderate |
Intervention NR Risk of bothersome soreness in preceding week Self‐report (yes/no) · patients with people doing unaccustomed exercise Stretching to prevent or reduce muscle soreness after exercise (2011) · Cochrane | OR 0.69 [0.59, 0.82] | 0 studies · 1 participants | Moderate |
Intervention NR Death · Children aged 6‐60 months with cerebral malaria Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria (2011) · Cochrane | RR 0.81 | 1 study · 156 participants | Low |
Intervention NR Major neurological sequelae · Children aged 6‐60 months with cerebral malaria Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Coma recovery time · Children aged 6‐60 months with cerebral malaria Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria (2011) · Cochrane | no estimate extracted | 1 study · 156 participants | Low |
Intervention NR Time to hospital discharge · Children aged 6‐60 months with cerebral malaria Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Need for ventilation · Children aged 6‐60 months with cerebral malaria Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Need for cardiopulmonary resuscitation · Children aged 6‐60 months with cerebral malaria Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · Children aged 6‐60 months with cerebral malaria Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria (2011) · Cochrane | no estimate extracted | 1 study · 156 participants | Low |
PHASE SPECIFIC TREATMENT (RISPERIDONE + CBT) + SPECIALISED TEAM vs SPECIALISED TEAM Leaving the study early ‐ by 12 months · patients with psychosis Early intervention for psychosis (2011) · Cochrane | no estimate extracted | 1 study · 59 participants | Moderate |
PHASE SPECIFIC TREATMENT (RISPERIDONE + CBT) + SPECIALISED TEAM vs SPECIALISED TEAM Progression to psychosis ‐ by 6 months · patients with psychosis Early intervention for psychosis (2011) · Cochrane | RR 0.27 [0.08, 0.89] | 1 study · 59 participants | Moderate |
PHASE SPECIFIC TREATMENT (RISPERIDONE + CBT) + SPECIALISED TEAM vs SPECIALISED TEAM Progression to psychosis ‐ by 12 months · patients with psychosis Early intervention for psychosis (2011) · Cochrane | RR 0.54 [0.23, 1.3] | 1 study · 59 participants | Moderate |
SPECIALISED TEAM vs STANDARD CARE Compliance with treatment ‐ treatment stopped in spite of need ‐ by one year · patients with psychosis Early intervention for psychosis (2011) · Cochrane | RR 0.2 [0.1, 0.42] | 1 study · 507 participants | Moderate |
SPECIALISED TEAM vs STANDARD CARE Compliance with treatment ‐ treatment stopped in spite of need ‐ by two years · patients with psychosis Early intervention for psychosis (2011) · Cochrane | RR 0.66 [0.29, 1.5] | 1 study · 436 participants | Moderate |
SPECIALISED TEAM vs STANDARD CARE Service use: 1. Average mean number of days per month in hospital ‐ by 5 years · patients with psychosis Early intervention for psychosis (2011) · Cochrane | no estimate extracted | 1 study · 547 participants | Moderate |
SPECIALISED TEAM vs STANDARD CARE Service use: 2. Not hospitalised ‐ by five years · patients with psychosis Early intervention for psychosis (2011) · Cochrane | RR 1.05 [0.9, 1.22] | 1 study · 547 participants | Moderate |
SPECIALISED TEAM vs STANDARD CARE Social outcomes: 1. Not living independently ‐ by 5 years · patients with psychosis Early intervention for psychosis (2011) · Cochrane | RR 0.42 [0.21, 0.83] | 1 study · 547 participants | Moderate |
SPECIALISED TEAM vs STANDARD CARE Social outcomes: 2. Not working or in education ‐ by 5 years · patients with psychosis Early intervention for psychosis (2011) · Cochrane | RR 1.06 [0.92, 1.23] | 1 study · 547 participants | Moderate |
Recombinant Human Erythropoietin vs Placebo Death · patients with anemia in people with AIDS Treatment for anemia in people with AIDS (2011) · Cochrane | RR 0.56 [0.08, 4.05] | 2 studies · 84 participants | Very low |
Intervention NR Per cent of patients who underwent successful reduction · acute anterior shoulder dislocation in adults Intra‐articular lignocaine versus intravenous analgesia with or without sedation for manual reduction of… (2011) · Cochrane | RR 0.95 [0.83, 1.1] | 5 studies · 211 participants | Low |
Reminder packages vs no reminder packages Adherence (% of pills taken) · people taking self‐administered medications Reminder packaging for improving adherence to self‐administered long‐term medications (2011) · Cochrane | no estimate extracted | 6 studies · 772 participants | Low |
Reminder packages vs no reminder packages Adherence (self‐ reported) · people taking self‐administered medications Reminder packaging for improving adherence to self‐administered long‐term medications (2011) · Cochrane | OR 0.89 [0.56, 1.4] | 2 studies · 339 participants | Very low |
Reminder packages vs no reminder packages Systolic blood pressure · people taking self‐administered medications Reminder packaging for improving adherence to self‐administered long‐term medications (2011) · Cochrane | no estimate extracted | 2 studies · 153 participants | Very low |
Reminder packages vs no reminder packages Diastolic blood pressure · people taking self‐administered medications Reminder packaging for improving adherence to self‐administered long‐term medications (2011) · Cochrane | no estimate extracted | 2 studies · 153 participants | Very low |
Reminder packages vs no reminder packages Glycated haemoglobin (HbA1c) level · people taking self‐administered medications Reminder packaging for improving adherence to self‐administered long‐term medications (2011) · Cochrane | no estimate extracted | 2 studies · 148 participants | Very low |
Any Psychosocial plus any Pharmacological vs any Pharmachological alone compared to Dropouts ‐ All studies objective · patients with opioid detoxification Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (2011) · Cochrane | RR 0.71 [0.59, 0.85] | 6 studies · 424 participants | Moderate |
Any Psychosocial plus any Pharmacological vs any Pharmachological alone compared to Dropouts ‐ Only studies with low risk of bias objeive · patients with opioid detoxification Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (2011) · Cochrane | RR 0.72 [0.58, 0.88] | 5 studies · 373 participants | High |
Any Psychosocial plus any Pharmacological vs any Pharmachological alone compared to Use of opiate during the treatment objective · patients with opioid detoxification Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (2011) · Cochrane | RR 0.82 [0.71, 0.93] | 4 studies · 320 participants | Moderate |
Any Psychosocial plus any Pharmacological vs any Pharmachological alone compared to Results at · patients with opioid detoxification Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (2011) · Cochrane | RR 0.66 [0.53, 0.82] | 3 studies · 208 participants | Moderate |
Any Psychosocial plus any Pharmacological vs any Pharmachological alone compared to Results at · patients with opioid detoxification Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (2011) · Cochrane | RR 0.84 [0.68, 1.04] | 2 studies · 89 participants | High |
Any Psychosocial plus any Pharmacological vs any Pharmachological alone compared to Compliance as clinical absences during the tratment objective · patients with opioid detoxification Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (2011) · Cochrane | RR 0.48 [0.38, 0.59] | 3 studies · 1138 participants | Moderate |
Oxime vs placebo Deaths · patients with acute organophosphate pesticide poisoning Oximes for acute organophosphate pesticide poisoning (2011) · Cochrane | OR 2.68 [0.93, 7.72] | 3 studies · 366 participants | Very low |
Oxime vs placebo Intermediate syndrome · patients with acute organophosphate pesticide poisoning Oximes for acute organophosphate pesticide poisoning (2011) · Cochrane | OR 3.4 [1.62, 7.17] | 1 study · 110 participants | Very low |
Oxime vs placebo Ventilated · patients with acute organophosphate pesticide poisoning Oximes for acute organophosphate pesticide poisoning (2011) · Cochrane | OR 2 [0.81, 4.95] | 3 studies · 366 participants | Very low |
Higher dose vs lower dose Deaths · patients with acute organophosphate pesticide poisoning Oximes for acute organophosphate pesticide poisoning (2011) · Cochrane | OR 0.38 [0.1, 1.47] | 4 studies · 479 participants | Very low |
Higher dose vs lower dose Intermediate syndrome · patients with acute organophosphate pesticide poisoning Oximes for acute organophosphate pesticide poisoning (2011) · Cochrane | OR 0.94 [0.24, 3.62] | 3 studies · 283 participants | Very low |
Higher dose vs lower dose Ventilated · patients with acute organophosphate pesticide poisoning Oximes for acute organophosphate pesticide poisoning (2011) · Cochrane | OR 0.72 [0.08, 6.35] | 2 studies · 272 participants | Very low |
Intervention NR Creatine phosphate 1g/day · patients with heart failure Creatine and creatine analogues in hypertension and cardiovascular disease (2011) · Cochrane | no estimate extracted | 1 study · 13 participants | Low |
Intervention NR Creatine 20g/day for 6 weeks · patients with heart failure Creatine and creatine analogues in hypertension and cardiovascular disease (2011) · Cochrane | no estimate extracted | 1 study · 13 participants | Low |
Intervention NR Creatine 20g/day for 10 days · patients with heart failure Creatine and creatine analogues in hypertension and cardiovascular disease (2011) · Cochrane | no estimate extracted | 1 study · 17 participants | Low |